PL443839A1 - Compound, diagnostic marker for gastric cancer, method of detecting enzymatic activity, method of diagnosing gastric cancer, kit comprising such a compound and uses of such a compound and method of treating gastric cancer - Google Patents

Compound, diagnostic marker for gastric cancer, method of detecting enzymatic activity, method of diagnosing gastric cancer, kit comprising such a compound and uses of such a compound and method of treating gastric cancer

Info

Publication number
PL443839A1
PL443839A1 PL443839A PL44383923A PL443839A1 PL 443839 A1 PL443839 A1 PL 443839A1 PL 443839 A PL443839 A PL 443839A PL 44383923 A PL44383923 A PL 44383923A PL 443839 A1 PL443839 A1 PL 443839A1
Authority
PL
Poland
Prior art keywords
compound
gastric cancer
stomach cancer
diagnosing
enzymatic activity
Prior art date
Application number
PL443839A
Other languages
Polish (pl)
Inventor
Adam LESNER
Natalia Gruba
Original Assignee
Urteste Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urteste Spółka Akcyjna filed Critical Urteste Spółka Akcyjna
Priority to PL443839A priority Critical patent/PL443839A1/en
Priority to PCT/PL2024/050014 priority patent/WO2024177524A1/en
Priority to JP2025548235A priority patent/JP2026506172A/en
Priority to CN202480013817.4A priority patent/CN120769986A/en
Priority to IL322860A priority patent/IL322860A/en
Priority to EP24717818.9A priority patent/EP4669964A1/en
Priority to AU2024226118A priority patent/AU2024226118A1/en
Priority to KR1020257031512A priority patent/KR20250143356A/en
Publication of PL443839A1 publication Critical patent/PL443839A1/en
Priority to MX2025009077A priority patent/MX2025009077A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem zgłoszenia jest nowy związek chemiczny, marker diagnostyczny do zastosowania medycznego, dokładniej w diagnostyce nowotworowej w szczególności w diagnostyce raka żołądka. Przedmiotem zgłoszenia jest także sposób in vitro wykrywania aktywności enzymatycznej obecnej w płynie ustrojowym osobnika, w szczególności pochodzącej z komórek raka żołądka z użyciem takiego związku. Przedmiotem zgłoszenia jest ponadto sposób in vitro diagnozowania raka żołądka z użyciem takiego związku, zestaw zawierający taki związek oraz zastosowanie takiego związku do wykrywania aktywności enzymatycznej swoistej dla raka żołądka i zastosowanie takiego związku do diagnozowania raka żołądka. Przedmiotem zgłoszenia jest także taki związek do zastosowania jako marker diagnostyczny raka żołądka oraz sposób leczenia raka żołądka obejmujący etap przeprowadzania sposobu diagnozowania raka żołądka, jak określono powyżej z zastosowaniem takiego związku.The subject of the application is a new chemical compound, a diagnostic marker for medical use, more specifically in cancer diagnostics, in particular in the diagnosis of stomach cancer. The subject of the application is also an in vitro method of detecting enzymatic activity present in a body fluid of an individual, in particular originating from stomach cancer cells using such a compound. The subject of the application is also an in vitro method of diagnosing stomach cancer using such a compound, a kit containing such a compound and the use of such a compound for detecting enzymatic activity specific for stomach cancer and the use of such a compound for diagnosing stomach cancer. The subject of the application is also such a compound for use as a diagnostic marker for stomach cancer and a method of treating stomach cancer comprising the step of carrying out a method of diagnosing stomach cancer as defined above using such a compound.

PL443839A 2023-02-21 2023-02-21 Compound, diagnostic marker for gastric cancer, method of detecting enzymatic activity, method of diagnosing gastric cancer, kit comprising such a compound and uses of such a compound and method of treating gastric cancer PL443839A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL443839A PL443839A1 (en) 2023-02-21 2023-02-21 Compound, diagnostic marker for gastric cancer, method of detecting enzymatic activity, method of diagnosing gastric cancer, kit comprising such a compound and uses of such a compound and method of treating gastric cancer
PCT/PL2024/050014 WO2024177524A1 (en) 2023-02-21 2024-02-19 Compound, diagnostic marker for stomach cancer, method for detecting enzymatic activity, method for the diagnosis of stomach cancer, kit comprising the compound, uses of the compound and method for the treatment of stomach cancer
JP2025548235A JP2026506172A (en) 2023-02-21 2024-02-19 Compound, diagnostic marker for gastric cancer, method for detecting enzyme activity, method for diagnosing gastric cancer, kit containing the compound, use of the compound, and method for treating gastric cancer
CN202480013817.4A CN120769986A (en) 2023-02-21 2024-02-19 Compound, diagnostic marker for gastric cancer, method for detecting enzyme activity, method for diagnosing gastric cancer, kit comprising the compound, use of the compound, and method for treating gastric cancer
IL322860A IL322860A (en) 2023-02-21 2024-02-19 Compound, diagnostic marker for stomach cancer, method for detecting enzymatic activity, method for the diagnosis of stomach cancer, kit comprising the compound, uses of the compound and method for the treatment of stomach cancer
EP24717818.9A EP4669964A1 (en) 2023-02-21 2024-02-19 COMPOUND, DIAGNOSTIC MARKER FOR STOMACH CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY
AU2024226118A AU2024226118A1 (en) 2023-02-21 2024-02-19 Compound, diagnostic marker for stomach cancer, method for detecting enzymatic activity, method for the diagnosis of stomach cancer, kit comprising the compound, uses of the compound and method for the treatment of stomach cancer
KR1020257031512A KR20250143356A (en) 2023-02-21 2024-02-19 Compound, gastric cancer diagnostic marker, method for detecting enzyme activity, method for diagnosing gastric cancer, kit containing compound, use and method of compound for treating gastric cancer
MX2025009077A MX2025009077A (en) 2023-02-21 2025-08-01 Compound, diagnostic marker for stomach cancer, method for detecting enzymatic activity, method for the diagnosis of stomach cancer, kit comprising the compound, uses of the compound and method for the treatment of stomach cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL443839A PL443839A1 (en) 2023-02-21 2023-02-21 Compound, diagnostic marker for gastric cancer, method of detecting enzymatic activity, method of diagnosing gastric cancer, kit comprising such a compound and uses of such a compound and method of treating gastric cancer

Publications (1)

Publication Number Publication Date
PL443839A1 true PL443839A1 (en) 2024-08-26

Family

ID=90719853

Family Applications (1)

Application Number Title Priority Date Filing Date
PL443839A PL443839A1 (en) 2023-02-21 2023-02-21 Compound, diagnostic marker for gastric cancer, method of detecting enzymatic activity, method of diagnosing gastric cancer, kit comprising such a compound and uses of such a compound and method of treating gastric cancer

Country Status (9)

Country Link
EP (1) EP4669964A1 (en)
JP (1) JP2026506172A (en)
KR (1) KR20250143356A (en)
CN (1) CN120769986A (en)
AU (1) AU2024226118A1 (en)
IL (1) IL322860A (en)
MX (1) MX2025009077A (en)
PL (1) PL443839A1 (en)
WO (1) WO2024177524A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090052236A (en) * 2007-11-20 2009-05-25 한국과학기술연구원 Quenched Fluorescent Sensor, Imaging Method and Use for Imaging Protease
KR20110039093A (en) * 2009-10-09 2011-04-15 한국과학기술연구원 In vitro kits for measuring protease activity and methods for preparing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3919911A1 (en) * 2020-06-04 2021-12-08 Urteste S.A. Novel diagnostic marker for prostate cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090052236A (en) * 2007-11-20 2009-05-25 한국과학기술연구원 Quenched Fluorescent Sensor, Imaging Method and Use for Imaging Protease
KR20110039093A (en) * 2009-10-09 2011-04-15 한국과학기술연구원 In vitro kits for measuring protease activity and methods for preparing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TM DE OLIVEIRA I IN.: "Clin Biochem. 2020 May:79:61-69. doi: 10.1016/j.clinbiochem.2020.02.010", "LABEL-FREE PEPTIDE QUANTIFICATION COUPLED WITH IN SILICO MAPPING OF PROTEASES FOR IDENTIFICATION OF POTENTIAL SERUM BIOMARKERS IN GASTRIC ADENOCARCINOMA PATIENTS" *

Also Published As

Publication number Publication date
CN120769986A (en) 2025-10-10
JP2026506172A (en) 2026-02-20
WO2024177524A1 (en) 2024-08-29
MX2025009077A (en) 2025-09-02
KR20250143356A (en) 2025-10-01
IL322860A (en) 2025-10-01
AU2024226118A1 (en) 2025-08-21
EP4669964A1 (en) 2025-12-31

Similar Documents

Publication Publication Date Title
US9983210B2 (en) Salivary mRNA profiling, biomarkers and related methods and kits of parts
JP2024054187A (en) Methods for Analysing Pluripotent Stem Cell Biomarkers and Their Implementation - Patent application
PL439405A1 (en) Compound - a diagnostic marker for liver cancer, method for detecting enzyme activity, method for diagnosing liver cancer, kit comprising such a compound and uses of such a compound and method for treating liver cancer
Neuberger et al. Biosynthesis of porphyrins and congenital porphyria
PL440782A1 (en) Compound - a diagnostic marker for bowel cancer, a method for detecting enzymatic activity, method for diagnosing intestinal cancer, a kit containing such a compound, and uses of such a compound and a method for treating intestinal cancer
PL445390A1 (en) Compound, diagnostic marker for breast cancer, method of detecting enzymatic activity, method of diagnosing breast cancer, kit comprising such a compound and uses of such a compound and method of treating breast cancer
PL441568A1 (en) Compound - a diagnostic marker for endometrial cancer, method for detecting enzymatic activity, method for diagnosing endometrial cancer, kit containing such a compound, and uses of such a compound and method for treating endometrial cancer
PL448268A1 (en) Compound - diagnostic marker for brain tumor, method of detecting enzymatic activity, method of diagnosing brain tumor, kit containing such compound and uses of such compound and method of treating brain tumor
PL443432A1 (en) Compound - diagnostic marker for biliary tract cancer, method of detecting enzymatic activity, method of diagnosing biliary tract cancer, kit containing such a compound and uses of such a compound and method of treating biliary tract cancer
PL440976A1 (en) A kidney cancer diagnostic marker compound, a method for detecting enzyme activity, a method for diagnosing kidney cancer, a kit containing such a compound, and uses of such a compound and a method for treating kidney cancer
PL439760A1 (en) Compound - a diagnostic marker for lung cancer, method for diagnosing lung cancer, a kit comprising such a compound and applications of such a compound and lung cancer treating method
CN1256713A (en) Rapid diagnosis method for cancer
MX2025009077A (en) Compound, diagnostic marker for stomach cancer, method for detecting enzymatic activity, method for the diagnosis of stomach cancer, kit comprising the compound, uses of the compound and method for the treatment of stomach cancer
MX2025003506A (en) Compound - diagnostic marker for ovarian cancer, method for detecting enzymatic activity, method for diagnosis of ovarian cancer, kit comprising the compound, uses of the compound and method for the treatment of ovarian cancer
ATE429440T1 (en) FORMS OF PROSTATE-SPECIFIC ANTIGENS AND METHOD FOR THE DETECTION THEREOF
Ekesiobi et al. Evaluation of invasive and non-invasive methods of diagnosing Helicobacter pylori infection in Port Harcourt, Nigeria
FR2840905B1 (en) MONOCLONAL ANTI-AURORA-A ANTIBODY, METHOD FOR OBTAINING SAME, AND USES THEREOF IN CANCER DIAGNOSIS AND TREATMENT
RU2327997C1 (en) Method of chronic abacterial prostatitis differential diagnostics
Xie et al. miR-582-5p regulates cell stemness and recurrence in bladder cancer via targeting CD81
Chan-Chan et al. PAK6: a potential anti-cancer target
Buetas Giménez Exploring the role of oral microbiota in colorectal cancer
SA123447208B1 (en) Signs and methods of diagnosing heat stroke
RU2440583C2 (en) Method of helicobacter pylori infection diagnostics in patients with surgical pathology of abdominal cavity organs
UA138903U (en) METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS
UA140125U (en) METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS